Last reviewed 2026-04-22 · How we verify

Tenofovir disoproxil/emtricitabine/rilpivirine

Tenofovir disoproxil/emtricitabine/rilpivirine is a Antiretroviral combination (NRTI + NNRTI) Small molecule drug developed by Sheba Medical Center. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as a complete regimen for antiretroviral therapy. Also known as: eviplera, complera.

This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients.

This combination inhibits HIV reverse transcriptase and integrase to block viral replication and reduce viral load in HIV-infected patients. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as a complete regimen for antiretroviral therapy.

At a glance

Mechanism of action

Tenofovir disoproxil and emtricitabine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to terminate viral DNA chain elongation. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks its catalytic activity. Together, these three agents provide complementary inhibition of HIV reverse transcriptase, a critical enzyme for viral replication.

Approved indications

• HIV-1 infection in treatment-naïve and treatment-experienced patients
• HIV-1 infection as a complete regimen for antiretroviral therapy

Common side effects

• Nausea
• Diarrhea
• Headache
• Rash
• Elevated liver enzymes
• Renal impairment (tenofovir-related)

Key clinical trials

• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
• Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
• Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
• Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
• Research on the Psychological Status of Patients With HIV-1 Infection
• Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Tenofovir disoproxil/emtricitabine/rilpivirine CI brief — competitive landscape report
• Tenofovir disoproxil/emtricitabine/rilpivirine updates RSS · CI watch RSS
• Sheba Medical Center portfolio CI

Frequently asked questions about Tenofovir disoproxil/emtricitabine/rilpivirine

Related

• Drug class: All Antiretroviral combination (NRTI + NNRTI) drugs
• Target: All drugs targeting HIV reverse transcriptase
• Manufacturer: Sheba Medical Center — full pipeline
• Therapeutic area: All drugs in Infectious Disease / Virology
• Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
• Indication: Drugs for HIV-1 infection as a complete regimen for antiretroviral therapy
• Also known as: eviplera, complera
• Compare: Tenofovir disoproxil/emtricitabine/rilpivirine vs similar drugs
• Pricing: Tenofovir disoproxil/emtricitabine/rilpivirine cost, discount & access